Policy and Legislation
Senate Bill 17 calls for price transparency; drug companies would have to announce large price hikes, give detailed justification explaining hike.
Echoing sentiments from LGBT groups made when the OCR director was hired in March, a group of Democratic Senators is denouncing the appointment.
Many cited efficiency as a main reason for their stance, saying it's often a hassle to work with many different insurance companies.
By many accounts, loss of subsidies would wreck the market if successful, stranding up to 12 million without coverage.
The Assistance and Alignment tracks of the Accountable Health Communities Model will begin on May 1 for a five-year performance period.
Bill would close loophole in FDA law which allows branded drug makers to use closed distribution networks to block generics.
Proposals are fueled both by a fear of losing gains under the ACA, sense that the law doesn't go far enough toward covering everyone, cutting costs.
In 2015-2016, teaching health centers turned out more than 700 new doctors, could nearly close the physician shortage by 2020.
If coverage of the low spenders declines, insurers' ability to offer affordable coverage to high spenders with greater need will also decline.
The House speaker said the idea, modeled after Maine program, has support of both moderates and the conservative Freedom Caucus.